Market Size - US: $1 Billion, Worldwide: $2 Billion
Our independent lab compared our product, Mast-R-Prep, to the market leader Chloraprep (Chloraprep was acquired by Cardinal Health for $490 million in 2008). Our in vitro results showed superior delivery of Chlorhexidine Gluconate (CHG) over time compared to Chloraprep.

Our independent lab compared our product, Mast-R-Prep, to the market leader Chloraprep in vivo. Our in vivo results showed Mast R Prep's superior bacterial kill rate over time compared to Chloraprep.

Product Licensed - October 2009